Frontiers in Pharmacology
Preclinical pharmacokinetic modeling and clinical translation of SIG001, a novel anti-cancer therapeutic antibody targeting on cancer-derived sialylated IgG
Introduction Sialylated immunoglobulin G (SIA-IgG) has emerged as a novel therapeutic target selectively overexpressed in epithelial-derived malignancies. The humanized monoclonal antibody SIG001 binds specifically to tumor-associated SIA-IgG and is regarded as a promising first-in-class candidate for the broad-spectrum treatment of epithelial cancers. Methods The pharmacokinetic (PK) behavior of SIG001 was evaluated in both cynomolgus monkeys and mice following intravenous administration. Utilizing modeling approa …